U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated ...
CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage ...
The MarketWatch News Department was not involved in the creation of this content. -- Potential first-in-class, and industry-leading DNA polymerase Theta (Pol ) inhibitor, ART6043 demonstrated an ...
Trial in progress: First-in-human study of PFL-721/STX-721 in participants with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations. This is an ASCO ...
The MarketWatch News Department was not involved in the creation of this content. CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 -- Artios Pharma Limited ("Artios"), a biopharmaceutical ...
Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results